| Literature DB >> 28255247 |
Keying Che1, Yang Zhao2, Xiao Qu1, Zhaofei Pang1, Yang Ni3, Tiehong Zhang3, Jiajun Du4, Hongchang Shen3.
Abstract
PURPOSE: Gastric carcinoma (GC) is a highly aggressive cancer and one of the leading causes of cancer-related deaths worldwide. Histopathological evaluation pertaining to invasiveness is likely to provide additional information in relation to patient outcome. In this study, we aimed to evaluate the prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma.Entities:
Keywords: gastric carcinoma; invasion type; metastasis; pathology; prognosis
Year: 2017 PMID: 28255247 PMCID: PMC5325090 DOI: 10.2147/OTT.S127762
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Associations between invasion types and clinicopathological characteristics of 296 patients with gastric adenocarcinoma
| Variables | Tumor budding
| Single cell invasion
| Large cell invasion
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| (−) | (+) | (−) | (+) | (−) | (+) | ||||
| Age (years) | 0.362 | 0.690 | 0.164 | ||||||
| ≤60 | 67 (22.6%) | 72 (24.3%) | 50 (16.9%) | 89 (30.1%) | 120 (40.5%) | 19 (6.4%) | |||
| >60 | 84 (28.4%) | 73 (24.7%) | 60 (20.3%) | 97 (32.8%) | 126 (42.6%) | 31 (10.5%) | |||
| Sex | 0.441 | 0.640 | 0.180 | ||||||
| Male | 113 (38.2%) | 114 (38.5%) | 86 (29.1%) | 141 (47.6%) | 185 (62.5%) | 42 (14.2%) | |||
| Female | 38 (12.8%) | 31 (10.5%) | 24 (8.1%) | 45 (15.2%) | 61 (20.6%) | 8 (2.7%) | |||
| T classification | <0.001 | <0.001 | 0.005 | ||||||
| T1 + T2 | 63 (21.3%) | 21 (7.1%) | 55 (18.6%) | 29 (9.8%) | 78 (26.4%) | 6 (2.0%) | |||
| T3 + T4 | 88 (29.7%) | 124 (41.9%) | 55 (18.6%) | 157 (53.0%) | 168 (56.8%) | 44 (14.9%) | |||
| N classification | <0.001 | <0.001 | 0.002 | ||||||
| N0 | 66 (22.3%) | 31 (10.5%) | 60 (20.3%) | 37 (12.5%) | 90 (30.4%) | 7 (2.4%) | |||
| N1 + N2 + N3 | 85 (28.7%) | 114 (38.5%) | 50 (16.9%) | 149 (50.3%) | 156 (52.7%) | 43 (14.5%) | |||
| M classification | 0.005 | 0.001 | <0.001 | ||||||
| M0 | 127 (42.9%) | 102 (34.5%) | 97 (32.8%) | 132 (44.6%) | 201 (67.9%) | 28 (9.5%) | |||
| M1 | 24 (8.1%) | 43 (14.5%) | 13 (4.4%) | 54 (18.2%) | 45 (15.2%) | 22 (7.4%) | |||
| Pathological stage | <0.001 | <0.001 | 0.003 | ||||||
| Stage I + II | 77 (26.0%) | 30 (10.1%) | 68 (23.0%) | 39 (13.2%) | 98 (33.1%) | 9 (3.0%) | |||
| Stage III + IV | 74 (25.0%) | 115 (38.9%) | 42 (14.2%) | 147 (49.7%) | 148 (50.0%) | 41 (13.9%) | |||
| Tumor differentiation degree | <0.001 | <0.001 | 0.075 | ||||||
| Grade I + I–II | 76 (25.7%) | 123 (41.6%) | 52 (17.6%) | 147 (49.7%) | 160 (54.1%) | 39 (13.2%) | |||
| Grade II + III | 75 (25.3%) | 22 (7.4%) | 58 (19.6%) | 39 (13.2%) | 86 (29.1%) | 11 (3.7%) | |||
| Tumor budding | <0.001 | <0.001 | |||||||
| (−) | – | – | 96 (32.4%) | 55 (18.6%) | 137 (46.3%) | 14 (4.7%) | |||
| (+) | – | – | 14 (4.7%) | 131 (44.3%) | 109 (36.8%) | 36 (12.2%) | |||
| Large cell invasion | <0.001 | 0.001 | |||||||
| (−) | 137 (46.3%) | 109 (36.8%) | 102 (34.5%) | 144 (48.6%) | – | – | |||
| (+) | 14 (4.7%) | 36 (12.2%) | 8 (2.7%) | 42 (14.2%) | – | – | |||
| Single cell invasion | <0.001 | 0.001 | |||||||
| (−) | 96 (32.4%) | 14 (4.7%) | – | – | 102 (34.5%) | 8 (2.7%) | |||
| (+) | 55 (18.6%) | 131 (44.3%) | – | – | 144 (48.6%) | 42 (14.2%) | |||
| Fibrosis | 0.098 | 0.321 | 0.022 | ||||||
| (+) | 63 (21.3%) | 69 (23.3%) | 47 (15.9%) | 85 (28.7%) | 103 (34.8%) | 29 (9.8%) | |||
| (++) | 53 (17.9%) | 55 (18.6%) | 38 (12.8%) | 70 (23.6%) | 92 (31.1%) | 16 (5.4%) | |||
| (+++) | 35 (11.8%) | 21 (7.1%) | 25 (8.4%) | 31 (10.5%) | 51 (17.2%) | 5 (1.7%) | |||
| Mitosis | <0.001 | <0.001 | <0.001 | ||||||
| (−) | 100 (33.8%) | 42 (14.2%) | 83 (28.0%) | 59 (19.9%) | 133 (44.9%) | 9 (3.0%) | |||
| (+) | 51 (17.2%) | 103 (34.8%) | 27 (9.1%) | 127 (42.9%) | 113 (38.2%) | 41 (13.9%) | |||
| Smoking or drinking history | 0.993 | 0.300 | 0.688 | ||||||
| Yes | 52 (17.6%) | 50 (16.9%) | 42 (14.2%) | 60 (20.3%) | 86 (29.1%) | 16 (5.4%) | |||
| No | 99 (33.4%) | 95 (32.1%) | 68 (23.0%) | 126 (42.6%) | 160 (54.1%) | 34 (11.5%) | |||
Notes: Degree of tumor differentiation: grade I, poorly differentiated; grade II, moderately and poorly differentiated; grade III, moderately differentiated; IV, well differentiated. P<0.05 was considered significant.
Abbreviations: T, tumor; N, node; M, metastasis.
Figure 1Microscopic observations for gastric adenocarcinoma (HE stain).
Notes: (A) Tumor budding (arrows) was defined as a cluster of tumor cells composed of fewer than five tumor cells and was evaluated at 100× magnification. (B) Tumor budding (arrows) evaluated at 400× magnification. (C) Single cell invasion indicated by arrows at 400× magnification. (D) Large cell invasion was defined as a tumor cell whose nucleus diameter was quadruple the size of a small nearby lymphocyte. Indicated by arrows at 400× magnification. (E) Mitosis indicated by arrows at 400× magnification. (F) Fibrosis was confirmed if the area of fibrosis was >60% of the microscopic field. Evaluated at 100× magnification.
Abbreviation: HE, hematoxylin and eosin.
Univariate Cox regression analysis of clinical and pathological characteristics
| Variables | HR | 95% CI | |
|---|---|---|---|
| Age (years) | |||
| ≤60 | 1.000 | Reference | – |
| >60 | 1.556 | 1.116–2.168 | 0.009 |
| Sex | |||
| Male | 1.000 | Reference | – |
| Female | 0.746 | 0.497–1.121 | 0.159 |
| T classification | |||
| T1 | 1.000 | Reference | <0.001 |
| T2 | 5.162 | 1.471–18.117 | 0.010 |
| T3 | 10.607 | 3.320–33.886 | <0.001 |
| T4 | 15.324 | 4.823–48.683 | <0.001 |
| N classification | |||
| N0 | 1.000 | Reference | <0.001 |
| N1 | 2.700 | 1.417–5.147 | 0.003 |
| N2 | 4.234 | 2.426–7.390 | <0.001 |
| N3 | 6.233 | 3.750–10.360 | <0.001 |
| M classification | |||
| M0 | 1.000 | Reference | – |
| M1 | 2.844 | 2.027–3.989 | <0.001 |
| Pathological stage | |||
| Stage I | 1.000 | Reference | <0.001 |
| Stage II | 2.767 | 0.961–7.964 | 0.059 |
| Stage III | 10.972 | 4.432–27.163 | <0.001 |
| Stage IV | 16.701 | 6.666–41.845 | <0.001 |
| Tumor differentiation degree | |||
| Grade I | 1.000 | Reference | 0.110 |
| Grades I–II | 0.729 | 0.484–1.095 | 0.128 |
| Grade II | 0.690 | 0.470–1.014 | 0.059 |
| Grade III | 0.228 | 0.032–1.640 | 0.142 |
| Tumor budding | |||
| (−) | 1.000 | Reference | – |
| (+) | 2.260 | 1.617–3.159 | <0.001 |
| Large cell invasion | |||
| (−) | 1.000 | Reference | – |
| (+) | 2.466 | 1.700–3.578 | <0.001 |
| Single cell invasion | |||
| (−) | 1.000 | Reference | – |
| (+) | 3.553 | 2.349–5.374 | <0.001 |
| Fibrosis | |||
| (+) | 1.000 | Reference | – |
| (++) | 0.767 | 0.538–1.092 | 0.141 |
| (+++) | 0.517 | 0.315–0.848 | 0.009 |
| Mitosis | |||
| (−) | 1.000 | Reference | – |
| (+) | 1.419 | 1.022–1.971 | 0.037 |
| Smoking or drinking history | |||
| No | 1.000 | Reference | – |
| Yes | 1.350 | 0.969–1.881 | 0.076 |
| WHO classification | |||
| Papillary gastric carcinoma | 1.000 | Reference | 0.013 |
| Tubular adenocarcinoma | 0.440 | 0.267–0.726 | 0.001 |
| Mucinous gastric carcinoma | 0.863 | 0.475–1.567 | 0.628 |
| Signet ring cell carcinoma | 0.748 | 0.404–1.382 | 0.353 |
| Low-differentiated adenocarcinoma | 0.844 | 0.485–1.470 | 0.550 |
| Undifferentiated adenocarcinoma | 1.158 | 1.158–0.739 | 0.523 |
| Lauren classification | |||
| Intestinal type | 1.000 | Reference | – |
| Diffuse type | 2.563 | 1.789–3.673 | <0.001 |
| Goseki classification | |||
| I | 1.000 | Reference | <0.001 |
| II | 1.890 | 1.093–3.267 | 0.023 |
| III | 2.634 | 1.684–4.119 | <0.001 |
| IV | 2.202 | 1.350–3.594 | 0.002 |
| Pathological classification | |||
| I | 1.000 | Reference | – |
| II | 2.820 | 1.568–5.071 | 0.001 |
| III | 3.907 | 2.375–6.425 | <0.001 |
| IV | 6.028 | 3.345–10.865 | <0.001 |
Abbreviations: CI, confidence interval; HR, hazard ratio; WHO, World Health Organization; T, tumor; N, node; M, metastasis.
Figure 2Overall survival (OS) figures pertaining to tumor budding (A), single cell invasion (B), large cell invasion (C), and mitotic count (D) in gastric adenocarcinoma.
Notes: (A) Kaplan–Meier survival curve for tumor budding in patients with gastric adenocarcinoma. The OS of cases with high-grade tumor budding was shorter than for cases exhibiting low-grade budding (P<0.001). (B) Patients with single cell invasion had shorter OS compared to those without single cell invasion (P<0.001). (C) Patients with large cell invasion had shorter OS compared to those without large cell invasion (P<0.001). (D) Patients with high mitotic count had shorter OS compared to those without high mitotic count (P=0.035).
Figure 3Survival curves according to different classification systems in gastric adenocarcinoma.
Notes: (A) Kaplan–Meier survival curve of WHO classification in patients with gastric adenocarcinoma. Papillary carcinoma showed statistically significant differences with tubular carcinoma subtype (P=0.001) but not with other subtypes (mucinous carcinoma, P=0.628; signet ring cell carcinoma, P=0.353; low-differentiated carcinoma, P=0.550; and undifferentiated carcinoma, P=0.528). P, T, M, S, L, and U represent papillary carcinoma, tubular carcinoma, mucinous carcinoma, signet ring cell carcinoma, minimally differentiated carcinoma, and undifferentiated carcinoma, respectively. (B) According to the Lauren classification, diffuse-type patients have unfavorable prognosis (P<0.001). I and D represent intestinal-type and diffuse-type gastric adenocarcinoma, respectively. (C) According to the Gosrki classification, the well-differentiated grades I and II had higher survival rates than the poorly differentiated grades III and IV. Grade I showed statistically significant differences compared with grades II, III, and IV (P=0.023, P<0.001, and P=0.002). I: well-differentiated and mucin-poor areas of tumor. II: well-differentiated and mucin-rich parts of the tumor. III: poorly differentiated and mucin-poor parts of the tumor. IV: poorly differentiated and mucin-rich parts of the tumor. (D) According to the new pathological classification, grade I showed statistically significant difference from grades II, III, and IV (P=0.001, P<0.001, and P<0.001). I: patients without tumor budding, single cell invasion, and large cell invasion. II: patients with single cell invasion. III: patients with tumor budding and single cell invasion. IV: patients with tumor budding, single cell invasion, and large cell invasion.
Abbreviation: WHO, World Health Organization.
Multivariate Cox regression analysis of clinical and pathological characteristics
| Factors | Category | HR | 95% CI | |
|---|---|---|---|---|
| Age (years) | ≤60 | 1.000 | Reference | – |
| >60 | 1.578 | 1.121–2.221 | 0.009 | |
| Large cell invasion | (−) | 1.000 | Reference | – |
| (+) | 1.566 | 1.051–2.333 | 0.028 | |
| Tumor budding | (−) | 1.000 | Reference | – |
| (+) | 1.568 | 1.044–2.354 | 0.030 | |
| Mitosis | (−) | 1.000 | Reference | – |
| (+) | 0.878 | 0.611–1.263 | 0.484 | |
| Pathological stage | I | 1.000 | Reference | – |
| II | 2.280 | 0.786–6.616 | 0.129 | |
| III | 8.855 | 3.514–22.317 | <0.001 | |
| IV | 12.699 | 4.959–32.520 | <0.001 | |
| Tumor differentiation degree | Grade I | 1.000 | Reference | – |
| Grades I–II | 0.827 | 0.541–1.264 | 0.380 | |
| Grade II | 1.146 | 0.726–1.810 | 0.557 | |
| Grade III | 0.639 | 0.085–4.794 | 0.663 | |
| Age (years) | ≤60 | 1.000 | Reference | – |
| >60 | 1.677 | 1.192–2.358 | 0.003 | |
| Large cell invasion | (−) | 1.000 | Reference | – |
| (+) | 1.699 | 1.145–2.522 | 0.008 | |
| Single cell invasion | (−) | 1.000 | Reference | – |
| (+) | 2.385 | 1.562–3.787 | <0.001 | |
| Mitosis | (−) | 1.000 | Reference | – |
| (+) | 0.789 | 0.547–1.136 | 0.203 | |
| Pathological stage | I | 1.000 | Reference | – |
| II | 2.068 | 0.708–6.038 | 0.184 | |
| III | 7.237 | 2.846–18.401 | <0.001 | |
| IV | 10.259 | 3.962–26.564 | <0.001 | |
| Tumor differentiation degree | Grade I | 1.000 | Reference | – |
| Grades I–II | 0.802 | 0.530–1.215 | 0.298 | |
| Grade II | 1.144 | 0.752–1.740 | 0.529 | |
| Grade III | 0.712 | 0.095–5.354 | 0.741 | |
Abbreviations: CI, confidence interval; HR, hazard ratio.